986 Pharmacy

The American healthcare system leaves millions of patients underserved by the impersonal, transaction-oriented model of corporate chain pharmacies. Long wait times, pharmacists too overwhelmed to counsel patients, language barriers, and one-size-fits-all service models create a real vacuum in community health delivery — particularly for elderly patients, non-English speakers, and those managing complex chronic conditions. 986 Pharmacy was built to fill exactly that gap. Founded in 2014 under the parent company 986 Degrees Corporation, the brand was co-founded by Dr. Ken Thai, Vijay Amarshi, Dr. Henry Chang, and Sally Chan, Esq. — a team comprising three pharmacists, a lawyer, and a creative professional who collectively brought clinical depth, legal rigor, and operational creativity to the independent pharmacy model. The first physical location opened in 2015 in La Verne, California, and the brand has since expanded to include seven franchised retail locations across Southern California, four specialty pharmacies operating across California, Nevada, and Texas, and an infusion pharmacy launched in Anaheim, California, in 2017. With 8 total units currently operating, 7 of which are franchised and the remaining company-owned units at zero, 986 Pharmacy is a lean but purposefully structured franchise system. The brand's fourth specialty pharmacy opened in Pasadena, California, in 2020, and its most recent expansion into Koreatown was completed in May 2023. For franchise investors evaluating the 986 Pharmacy franchise opportunity, this analysis is produced independently by PeerSense and is not sponsored, approved, or reviewed by 986 Degrees Corporation. The pharmacy services industry in North America represents a total addressable market that commanded a 53.2% global revenue share in 2024, and within that landscape, the 986 Pharmacy franchise occupies a differentiated, community-focused niche that is structurally positioned to benefit from the secular shift away from chain pharmacy consolidation.

The pharmacy industry is one of the most durable and macro-supported categories in franchise investment, driven by demographic inevitabilities and chronic disease prevalence that are immune to recessionary cycles. The global pharmacy market was estimated at USD 1.35 trillion in 2024 and is projected to reach USD 2.06 trillion by 2030, representing a compound annual growth rate of 7.3% between 2025 and 2030. Longer-range projections are even more aggressive: the global pharmacy market is estimated at USD 2,337.97 billion in 2025, with forecasts projecting growth to USD 4,569.34 billion by 2034 at a CAGR of 7.81%. The retail pharmacy segment specifically was worth approximately USD 689 billion globally in 2023 and is projected to reach USD 1,693 billion by 2032, growing at a CAGR of roughly 10.5% between 2024 and 2032. In the United States alone, prescription drug sales through retail pharmacies exceeded 364 billion USD in 2022, and the country accounted for over 40% of the global retail pharmacy market that same year. The secular tailwinds driving this growth are well-documented: an aging population with escalating medication needs, rising prevalence of chronic diseases, expanded Medicare and Medicaid coverage, and growing demand for specialty and compounding medications. The prescription segment dominated the global pharmacy market with a revenue share of 81.3% in 2024, reinforcing the centrality of Rx volume as a value driver in any pharmacy franchise investment. Independent pharmacies are projected to hold the largest distribution channel market share in retail pharmacy over the forecast period, creating an opening for branded independent models like the 986 Pharmacy franchise to capture outsized portions of this secular growth. The competitive environment, while dominated at the brand-recognition level by large institutions, is structurally fragmented at the community service layer — precisely the layer where 986 Pharmacy competes with personalized clinical care, multilingual staffing, and same-day delivery infrastructure.

The 986 Pharmacy franchise investment requires a total capital commitment ranging from $150,000 on the low end to $895,000 on the high end, reflecting the significant variability between a conversion of an existing pharmacy operation and a full ground-up buildout with specialty or infusion capabilities. Cross-referencing this against other published data points, one source cited a total investment range of $279,700 to $671,000, while another noted down payments for E2 visa-eligible investments starting at $100,000, confirming the franchise's accessibility to a range of investor profiles including international investors pursuing U.S. residency through the E2 visa program. The upfront franchise fee has been cited across various sources between $50,000 and $75,000, placing it in the mid-tier range for healthcare-adjacent franchise systems where fees frequently exceed $100,000 for medically complex service models. In the broader franchising industry, royalty rates typically range from 4% to 8% of gross sales, and advertising fund contributions generally fall between 1% and 3% of sales, providing a structural benchmark for modeling total ongoing fee obligations for the 986 Pharmacy franchise investment. The parent company, 986 Degrees Corporation, has a documented banking relationship with East West Bank dating to approximately 2012, with CEO Dr. Ken Thai citing SBA loan support as a key enabler of the company's early-stage growth — a relationship that may signal favorable SBA lending history for prospective franchisees seeking debt financing for their 986 Pharmacy franchise cost. The franchise system is currently not registered in states that require franchise registration, meaning prospective investors located in non-registration states should engage directly with 986 Degrees Corporation to confirm current registration status before advancing to due diligence. For investors comparing 986 Pharmacy franchise cost against category peers, the investment range is consistent with independent pharmacy conversions and below the threshold of many healthcare franchise systems that require significant clinical buildout and equipment procurement.

The 986 Pharmacy operating model is built around a high-touch, clinically enriched service delivery framework that demands an engaged, community-oriented franchisee rather than an absentee investor. Daily operations span retail prescription dispensing, specialty medication management, compounding services, infusion therapy, immunization programs, and medication therapy management — a breadth of clinical services that differentiates 986 Pharmacy locations from transactional chain competitors. The franchise's target service territory is defined as a 15-mile radius from the pharmacy location, with a strategic emphasis on elderly patients who generate disproportionately high prescription volume due to age-related chronic disease burden. Staffing is multilingual by design: 986 Pharmacy locations operate with team members fluent in English, Spanish, Mandarin, Cantonese, Korean, Vietnamese, Armenian, Farsi, and Russian, enabling the franchise to penetrate diverse urban and suburban community markets that are systematically underserved by monolingual chain pharmacies. The brand's operational philosophy extends to logistics: free daily local medication delivery is offered six days per week, and the brand has described its two-hour doorstep delivery capability as competitive with on-demand e-commerce fulfillment. Pharmacist training emphasizes patient-level personalization, with staff trained to recognize customers by face and name and to recall individual medication histories — a clinical customer experience standard that is difficult for high-volume chain competitors to replicate at scale. A documented case study involving Dr. Lilia Xu, Vice President of Business Development at 986 Degrees Corporation and owner-operator of 11 stores within the 986 Pharmacy Group network, demonstrated that the franchise system supports multi-unit operators with operational tools including Cardinal Health Reconciliation Plus powered by EnlivenHealth, which reduced accounts receivable reconciliation from an unmanageable manual burden to 1-2 hours per month across all 11 stores and achieved zero outstanding claims over 60 days — a meaningful operational benchmark for investors modeling cash flow management in a multi-unit 986 Pharmacy franchise portfolio.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for the 986 Pharmacy franchise, meaning prospective franchisees cannot rely on a franchisor-provided revenue benchmark when modeling unit-level economics. This is a material consideration in any due diligence process, and investors should request current FDD documents directly from 986 Degrees Corporation and consult with an independent franchise attorney before signing. While FDDs from 2017, 2018, 2019, and 2020 have been referenced as available through third-party FDD aggregators, the content of those documents' Item 19 sections has not been independently verified as containing specific gross revenue or net profit disclosures. In the absence of disclosed financial performance data, investors can contextualize unit-level revenue potential using industry benchmarks: the U.S. retail pharmacy market generated prescription drug sales exceeding 364 billion USD in 2022, and independent pharmacies serving Medicare and Medicaid populations — which 986 Pharmacy explicitly targets — benefit from recurring, insurance-reimbursed prescription volume with predictable refill cycles. Specialty pharmacy is a particularly high-value revenue segment; the specialty drug market is growing at rates meaningfully above the broader Rx market due to the increasing pipeline of biologic and oncology therapies requiring specialized dispensing and patient management. The franchise system reported 15 stores in operation as of January 2019, creating 203 jobs and serving over 50,000 patients — metrics that imply an average of roughly 3,333 patients per location at that point in the network's development, a patient census consistent with independently operating community pharmacies in suburban Southern California markets. Investors should also engage directly with existing 986 Pharmacy franchisees, including multi-unit operators within Dr. Lilia Xu's 11-store network, to solicit unfiltered perspectives on revenue trajectory, payer dynamics, and operating cost structures before committing capital to a 986 Pharmacy franchise investment.

The 986 Pharmacy franchise has demonstrated a consistent and accelerating growth trajectory since the first location opened in La Verne, California, in 2015. The franchise model itself was formalized in 2019 as part of a long-term strategic positioning to enable independent ownership within a branded, system-supported structure — a decision that aligned with the broader national trend toward independent pharmacy consolidation under franchise umbrellas. By January 2019, the network had already scaled to 15 stores, generating 203 jobs and serving over 50,000 patients, before the current FDD-reported unit count of 8 reflects what appears to be a subsequent restructuring or recalibration of the network footprint. The brand's multi-state presence — operating in California, Nevada, and Texas — demonstrates geographic diversification beyond its Southern California origin market. The leadership team provides a meaningful competitive moat: CEO Dr. Ken Thai holds a Doctoral degree from USC School of Pharmacy, has over 20 years of pharmacy experience, served as immediate-Past President of the California Pharmacists Association, and currently serves as an Adjunct Assistant Professor of Pharmacy Practice at both USC School of Pharmacy and Western University of Health Sciences, where he teaches entrepreneurship. Co-founder Dr. Henry Chang also holds a USC School of Pharmacy doctorate with over 20 years of independent and long-term care pharmacy ownership experience. Co-founder Sally Chan, Esq. serves as Vice President of Compliance and brings specialized expertise in business, real estate, and employment litigation through her firm West Themis Law, founded in 2008 and currently operating with her as managing partner. Co-founder Vijay Amarshi contributes digital marketing infrastructure through his prior founding of PCYNE, a digital marketing company, providing the franchise system with a growth-oriented digital acquisition capability. The franchise's expansion into Koreatown in May 2023 signals continued appetite for urban densification in multilingual Southern California markets where the brand's linguistic and clinical service model delivers a structural competitive advantage.

The ideal 986 Pharmacy franchisee is a healthcare-oriented entrepreneur or licensed pharmacist seeking to build an owner-operated or lightly managed community pharmacy business within a branded support infrastructure. While pharmacist licensure is not explicitly stated as a requirement, the clinical complexity of compounding, infusion, and specialty medication services within the 986 Pharmacy operating model strongly favors candidates with pharmacy or healthcare management backgrounds who can credibly oversee clinical operations and maintain regulatory compliance. The franchise system has demonstrated openness to multi-unit development, as evidenced by Dr. Lilia Xu's management of 11 stores across multiple states within the 986 Pharmacy Group network, suggesting that high-performing franchisees can scale significantly within the system. Geographic focus remains concentrated in California, Nevada, and Texas, with California — and particularly Southern California's diverse urban and suburban corridor — representing the brand's deepest market penetration and most developed operational infrastructure. The 15-mile territory radius creates meaningful local market exclusivity for franchisees willing to invest in community relationship building, particularly with assisted living facilities, boarding care homes, and 340B clinics, all of which represent recurring institutional revenue streams. Prospective franchisees interested in the E2 visa investment pathway should note that the franchise has been cited as eligible for E2 investment with entry points beginning at $100,000 in down payment, creating a relevant entry pathway for internationally based investors. The franchise's staff development culture — where employees have historically progressed into management roles and partnership opportunities — suggests a growth-oriented internal talent pipeline that benefits franchisees in competitive labor markets for pharmacy professionals.

For investors conducting serious due diligence on the 986 Pharmacy franchise opportunity, the investment thesis rests on several converging factors: a massive and accelerating global pharmacy market projected to exceed USD 2.06 trillion by 2030 at a 7.3% CAGR, a differentiated community-pharmacy model with multilingual clinical staffing and specialty service capabilities, a leadership team with over 40 combined years of pharmacy ownership and operational experience, and an initial investment range of $150,000 to $895,000 that is accessible relative to many healthcare franchise categories. The FPI Score of 46, rated Fair by the independent PeerSense scoring methodology, reflects the early-stage franchise system characteristics — limited disclosed unit count, absence of Item 19 financial performance data, and constrained geographic registration — that warrant heightened due diligence rather than automatic disqualification. The pharmacy sector's structural immunity to e-commerce disruption at the clinical services layer, combined with 986 Pharmacy's specialty and infusion capabilities that chain competitors cannot replicate at community scale, creates a defensible long-term positioning thesis. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark the 986 Pharmacy franchise investment against competing pharmacy and healthcare franchise opportunities across cost, support quality, and growth trajectory dimensions. Explore the complete 986 Pharmacy franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make your investment decision with the most comprehensive, unbiased analysis available anywhere on the internet.